181 related articles for article (PubMed ID: 23743566)
21. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Sugarbaker PH
Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
[TBL] [Abstract][Full Text] [Related]
22. Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors.
Guo AT; Li YM; Wei LX
World J Gastroenterol; 2012 Jun; 18(24):3081-8. PubMed ID: 22791943
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Yan TD; Links M; Xu ZY; Kam PC; Glenn D; Morris DL
Br J Surg; 2006 Oct; 93(10):1270-6. PubMed ID: 16838392
[TBL] [Abstract][Full Text] [Related]
24. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
25. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
26. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
27. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
Saxena A; Yan TD; Chua TC; Morris DL
Ann Surg Oncol; 2010 May; 17(5):1291-301. PubMed ID: 20039212
[TBL] [Abstract][Full Text] [Related]
28. [Pseudomyxoma peritonei. A review].
Elias D; Sabourin JC
J Chir (Paris); 1999 Dec; 136(6):341-7. PubMed ID: 10675825
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
30. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
Hsu KH; Chou CY; Chang YC
Hepatogastroenterology; 2007; 54(73):47-52. PubMed ID: 17419229
[TBL] [Abstract][Full Text] [Related]
32. Pseudomyxoma peritonei: a clinicopathologic analysis and follow-up of 21 patients.
Varona JF; Guerra JM; Salamanca J; Colina F; Lopez G; Morales M
Hepatogastroenterology; 2005; 52(63):812-6. PubMed ID: 15966210
[TBL] [Abstract][Full Text] [Related]
33. Role of preoperative sonography in the diagnosis and pathologic staging of pseudomyxoma peritonei.
Li Y; Guo A; Tang J; Wang L; Wang J; Yu D
J Ultrasound Med; 2013 Sep; 32(9):1565-70. PubMed ID: 23980216
[TBL] [Abstract][Full Text] [Related]
34. [Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
Sasaki A; Terashima M; Okamoto K; Ikeda K; Takagane A; Takiyama I; Shimada Y; Yamamoto M; Nakajima J; Sasaki N; Saito K
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1828-31. PubMed ID: 10560405
[TBL] [Abstract][Full Text] [Related]
35. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
36. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors.
Prayson RA; Hart WR; Petras RE
Am J Surg Pathol; 1994 Jun; 18(6):591-603. PubMed ID: 8179074
[TBL] [Abstract][Full Text] [Related]
37. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.
Murphy EM; Sexton R; Moran BJ
Dis Colon Rectum; 2007 Jan; 50(1):37-42. PubMed ID: 17115339
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of pseudomyxoma peritonei is developing].
Lepistö A; Osterlund P; Järvinen HJ
Duodecim; 2010; 126(14):1693-9. PubMed ID: 20804088
[TBL] [Abstract][Full Text] [Related]
39. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
Jess P; Iversen LH; Nielsen MB; Hansen F; Laurberg S; Rasmussen PC
Dis Colon Rectum; 2008 Jun; 51(6):868-74. PubMed ID: 18297361
[TBL] [Abstract][Full Text] [Related]
40. Cytoreduction including total gastrectomy for pseudomyxoma peritonei.
Sugarbaker PH
Br J Surg; 2002 Feb; 89(2):208-12. PubMed ID: 11856136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
